🔥 Nine Tumors, One Cancer Gene: The FDA Is Investigating a $2.1 Million Gene Therapy

The U.S. Food and Drug Administration just put a number on a risk that gene-therapy scientists have argued about for two decades: nine.

That is how many tumor reports Novartis has logged in children treated with Zolgensma, its spinal muscular atrophy gene therapy, since the drug was approved in 2019 (FDA). In three of those cases the tumors are tied to a cancer gene called GLI1. In two of them, the agency says it found the therapy’s own delivery virus inserted right next to that gene (RTTNews).

That is the precise thing researchers warned about when you use a virus to carry new DNA into a child’s cells. The FDA has now confirmed it inside an approved, $2.1 million medicine — not a lab experiment.

The gene therapy that pulled thousands of babies back from a fatal disease has, in a small number of them, done the one thing its critics feared.

🧠 Why This Matters

Zolgensma is not a fringe product. More than 6,000 children worldwide have received it across trials, managed-access programs, and commercial use (RTTNews). It treats spinal muscular atrophy, an inherited disease that, in its most severe form, kills most babies before their second birthday. One intravenous infusion, given before age two, replaces the broken SMN1 gene. For families, it has been the difference between a wheelchair-and-ventilator prognosis and a child who walks.

The delivery mechanism is the catch. Zolgensma uses an AAV9 virus to ferry the working gene into cells. For years the field’s working assumption was that AAV vectors mostly float inside the cell as loose DNA and rarely stitch themselves into a patient’s own chromosomes. The FDA now says that in at least two children, the vector did stitch itself in — and it landed next to GLI1, a gene that can drive cancer when it gets switched on.

“FDA has received postmarketing adverse event reports of malignancies in patients treated with Zolgensma.” — FDA Safety Communication, November 6, 2026

The term for this is insertional oncogenesis: a therapeutic gene accidentally flipping a cancer switch on its way in. It is the oldest fear in the gene-therapy playbook, and this is the first time the FDA has confirmed it in a widely used, approved AAV product.

📊 Deep Dive

Novartis disclosed the nine reports on November 5; the FDA followed with a safety communication on November 6 (TechTimes). The reported tumors span the central and peripheral nervous systems, the spinal and paraspinal regions, and the kidney. Three involve GLI1 overexpression; in two of those, tumor-tissue analysis showed Zolgensma’s vector DNA inserted near or within the gene. The third case is still being worked out.

Crucially, the agency extended the investigation to Itvisma, a newer spinal-fluid version of the same therapy, because it runs on the same vector and construct. No tumors have been reported after Itvisma yet.

Here is how the two products line up:

• Zolgensma — approved May 2019, for SMA patients under age 2, given as a single IV infusion, list price ~$2.125 million, 6,000+ patients treated, now linked to nine tumor reports.
• Itvisma — approved November 2025, for patients age 2 and up with a confirmed SMN1 mutation, given by intrathecal (spinal) injection, priced at $2.59 million, same AAV vector, zero tumor cases so far but now inside the probe.
• The shared risk — the FDA states the neoplasia risk “applies to both products” because they carry the identical vector and genetic payload.

For scale: the Zolgensma group (both products) booked $1.071 billion in sales over the first nine months of 2026, up from $925 million a year earlier (RTTNews). Novartis stock barely moved on the news, closing at $162.55 on November 6.

⚠️ The Catch

Before you write off gene therapy, read the denominator. Nine reports across more than 6,000 treated children is a rare signal, not an epidemic, and the FDA has not pulled the drug, issued a clinical hold, or slapped on a new black-box warning. The agency’s own verdict is blunt:

“The overall benefits of Zolgensma and Itvisma continue to outweigh their potential risks for their approved uses.” — FDA Safety Communication, November 6, 2026

Two caveats cut the other way. First, these are voluntary postmarketing reports, which tend to undercount rather than overcount, so the true rate is uncertain. Second, SMA itself is lethal untreated — for these families the comparison was never “therapy versus safety,” it was “therapy versus a disease that kills.” No tumor-related deaths have been reported. (Zolgensma’s existing boxed warning covers fatal liver injury, a separate issue from the tumors.)

🎯 What Happens Next

The FDA says it is “evaluating whether regulatory action is appropriate,” reviewing whether Zolgensma’s prescribing information and long-term follow-up studies adequately capture the insertional-oncogenesis risk (FDA). In practice that points to updated labeling and tighter long-term monitoring rather than a withdrawal. Doctors are now advised to watch treated children for tumor formation and report cases to Novartis and to the FDA’s MedWatch system.

Watch two things from here: whether any Itvisma cases surface, and whether the FDA asks Novartis for longer, more systematic cancer surveillance on children who were dosed as infants and will carry that vector for life.

🧩 Bigger Picture

This lands on far more than one drug. AAV vectors are the workhorse of modern gene therapy — the same basic delivery system sits behind a growing list of approved treatments for hemophilia, inherited blindness, and muscular dystrophy. The reassuring story the field has told regulators and parents is that AAV rarely integrates into human DNA. A confirmed case of it doing exactly that, in the most-used pediatric gene therapy on the market, forces every other AAV program to show its own long-term integration data.

That does not make these medicines reckless. It makes the monitoring that always sounded optional suddenly look mandatory. Gene therapy spent years promising one-and-done cures; the GLI1 cases are a reminder that “done” can mean decades of follow-up.

A virus rewrote a child’s genome to save their life. The hard part was always going to be everything that comes after.

---

Sources

• FDA — Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy (Nov 6, 2026)
• RTTNews — FDA Investigates Cancer Risk Associated With Novartis’ Zolgensma Gene Therapy
• TechTimes — FDA Confirms Gene Therapy Zolgensma Activated a Cancer Gene in Children, Extends Investigation to Itvisma

❓ Quick answers

Is Zolgensma being recalled over the cancer risk?

No. In its November 6, 2026 safety communication the FDA said the overall benefits of Zolgensma still outweigh its risks, and it issued no recall or clinical hold while it investigates.

How many children got tumors after Zolgensma?

Novartis disclosed nine tumor reports since the 2019 approval, out of more than 6,000 children treated worldwide; three cases involve the GLI1 gene and two show confirmed vector DNA insertion.

What is insertional oncogenesis in gene therapy?

It is when the therapy's delivery virus stitches its DNA into a patient's chromosome near a cancer-driving gene and activates it; the FDA confirmed this near the GLI1 gene in two Zolgensma cases in November 2026.